<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00182403</url>
  </required_header>
  <id_info>
    <org_study_id>CTMG-2005-FIDO</org_study_id>
    <secondary_id>#NA3640</secondary_id>
    <nct_id>NCT00182403</nct_id>
  </id_info>
  <brief_title>Fixed Dose Heparin Study</brief_title>
  <official_title>Fixed Dose Unfractionated Heparin for Initial Treatment of Venous Thromboembolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Stroke Foundation of Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <brief_summary>
    <textblock>
      FIDO was a multicentred randomized, open-label trial that compared fixed-dose UFH with
      fixed-dose LMWH for initial treatment of VTE. Patients were followed for 3 months during
      which they received warfarin (target INR 2.0-3.0).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The general objective was to simplify and reduce the cost of treatment of acute venous
      thromboembolism (VTE).Specific objectives were to compare the efficacy, safety and cost
      effectiveness of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) when
      each is administered subcutaneously (sc), twice daily, in weight -adjusted, fixed doses; and
      to determine if the anticoagulant response (anti-Factor Xa heparin levels, APTT results)
      influence efficacy and safety of UFH and LMWH, independently of dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1998</start_date>
  <completion_date>May 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic Venous Thromboembolism</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Bleeding</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>aXa ~6h after sc injection on 3rd day of treatment</measure>
  </secondary_outcome>
  <enrollment>866</enrollment>
  <condition>Venous Thromboembolism</condition>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Pulmonary Embolism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UFH 250 U/kg or LMWH 100 U/kg sc twice daily</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of acute venous thromboembolism (VTE,DVT and /or PE)

        Exclusion Criteria:

          -  Contraindication to subcutaneous (sc) route of administration (eg:shock (evidence of
             poor peripheral perfusion), major surgery within 48 hours)

          -  Active Bleeding process

          -  Comorbid condition limiting expected survival to less than 3 months

          -  Current treatment with therapeutic dose of UFH, LMWH, danaparoid sodium, or a direct
             thrombin inhibitor for more than 48 hours

          -  Currently on long term warfarin or heparin therapy

          -  Allergy to heparin or history of heparin induced thrombocytopenia

          -  Currently pregnant

          -  Contraindication to contrast media (eg: allergy or creatinine &gt;200 umol/L).

          -  Currently enrolled or will be enrolled in a competing study

          -  Geographically inaccessible for follow-up assessment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clive Kearon, MB Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamiton Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jim Julian, MMath</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster-Dept. of Clinical Epidemiology &amp;Biostatistics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamilton Health Sciences-General Campus</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamlton Health Sciences -McMaster Campus</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences-Henderson Campus</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA Pavillon du Saint-Sacrement</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middlemore</name>
      <address>
        <city>Otahuhu</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>New Zealand</country>
  </location_countries>
  <results_reference>
    <citation>Kearon C, Ginsberg JS, Julian JA, Douketis J, Solymoss S, Ockelford P, Jackson S, Turpie AG, MacKinnon B, Hirsh J, Gent M; Fixed-Dose Heparin (FIDO) Investigators. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA. 2006 Aug 23;296(8):935-42.</citation>
    <PMID>16926353</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <keyword>Unfractionated Heparin</keyword>
  <keyword>Low Molecular Weight Heparin</keyword>
  <keyword>Venous Thromboembolism</keyword>
  <keyword>APTT</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

